Wuhan General Group (China), Inc.

Equities

WUHN

US9825691051

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:46:40 2024-02-02 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-99.00%

2023	Institute of Biomedical Research Corp. Appoints Adrian J. Maizey to Advisory Board of M2Bio Sciences	CI
2022	Institute of Biomedical Research Corp. agreed to acquire Biomedical and Nutraceutical Assets of Wuhan General Group, Inc. (OTCPK : WUHN).	CI

Wuhan General Group, Inc. announced that it expects to receive $0.45 million in funding from ThreeD Capital Inc.

December 29, 2020

Wuhan General Group (China), Inc. (OTCPK:WUHN) announced a private placement of 1,500,000 units at $0.30 per unit for gross proceeds of $450,000 on December 30, 2020. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share of the company at $0.30 per share for three years from closing.

The transaction is expected to close at the latest January 30, 2021.

Latest news about Wuhan General Group (China), Inc.

Institute of Biomedical Research Corp. Appoints Adrian J. Maizey to Advisory Board of M2Bio Sciences	23-07-19	CI
Institute of Biomedical Research Corp. agreed to acquire Biomedical and Nutraceutical Assets of Wuhan General Group, Inc. (OTCPK : WUHN).	22-07-17	CI
Wuhan General Group, Inc. reached an agreement to acquire a 40% stake in Tsime Pharmaceuticals Ltd from Bataung Likate and other shareholders.	21-12-07	CI
Wuhan General Group, Inc. Announces Appointment of Michael Sachar as CEO of M2bio Sciences Food &Beverage	21-05-20	CI
Wuhan General Group, Inc. announced that it expects to receive $0.45 million in funding from ThreeD Capital Inc.	20-12-29	CI
Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa	19-11-07	CI
Wuhan General Group Appoints Hyder A. Khoja as Chief Scientific Officer	19-08-15	CI
Wuhan General Group, Inc. Announces Strategic Reorganization to Capitalize Medical Marijuana and Psilocybin Mushroom Industries; Appoints Luka Marjanovic as Head of Product Development for the MJ MedTech Division in South Africa	19-08-07	CI
Wuhan General Group, Inc. Expands Capacity to Produce Medicinal Marijuana and Mushrooms	19-05-17	CI
Wuhan General Group, Inc. Provides Revenue Guidance for the Second Quarter, Third Quarter and Fourth Quarter of 2019	19-03-28	CI
Wuhan General Group, Inc. Announces Executive Appointments	19-01-22	CI
Wuhan General Group, Inc. Announces Executive Changes	18-11-19	CI
EPlay and Wuhan Announce Strategic Partnership to Create New Medical Cannabis App	18-10-04	CI
Wuhan General Group, Inc. signed a non-binding Letter of Intent to acquire MJ MedTech Inc.	18-10-03	CI
Wuhan General Group, Inc. Appoints Anna Leralta Morera as Chief Medical Officer	18-09-18	CI
Wuhan General Group Seeks To Potential Acquisition	18-09-05	CI
The Board of Wuhan General Group, Inc. announced the spin-off of Strategic Development of Technology, Inc.	18-09-03	CI
USA Real Estate Holding Company & Wuhan General Group, Inc. Signs Letter of Intent to Launch Bitcoin & Cryptocurrency Mining Operations	18-06-19	CI
Wuhan General Group Inc. Announces Appointment of Ramy Kamaneh as the President and CEO	18-01-26	CI
Wuhan General Group Inc. Announces Board Changes	13-02-26	CI
Wuhan General Group Inc.(OTCPK:WUHN) dropped from NASDAQ Composite Index	12-06-14	CI
Wuhan General Group Inc. Appoints Yaojun Liu as Member of the Board	12-05-25	CI
Wuhan General Group Inc. Announces Management Changes	12-02-02	CI

Chart Wuhan General Group (China), Inc.

Duration

Period

More charts

Company Profile

Wuhan General Group (China) Inc is a South Africa-based bioceutical company. The Company is focused on alternative plant-based cannabinoids and mental health therapeutic research. Through its subsidiary, Neur.ai, the Company is engaged in developing a portfolio of receptor agonists based on neurotransformational medicine for the treatment of mental illness. The Company develops and commercializes a range of cannabidiol (CBD) and mushrooms-based products under the Dr. AnnaRx, Medspresso, and Liviana brands. The brands span across a range of premium CBD- and mushroom-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. In addition, the Company's research and clinical trials with psilocybin are aimed at new therapies that seek to help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Its Liviana brand offers CBD-infused raw honey and CBD-infused extra virgin olive oils.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WUHAN GENERAL GROUP (CHINA), INC.	-99.00%	55
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research